🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

AbCellera to Present at Upcoming Investor Conferences in December and January ow.ly/TkPn50Ucg0r

Visit our poster at AET US to explore how tailored T-cell engager design strategies can be leveraged to widen the therapeutic window, and enhance efficacy. #AntibodyEng

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology ow.ly/Toyx50UFhrA

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025 ow.ly/ZUq350UKycu

AbCellera to Participate at Upcoming Investor Conferences in March ow.ly/6ZMQ50UY6bF

AbCellera Reports Full Year 2024 Business Results ow.ly/LbYx50V7X3x

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 ow.ly/ioWA50Vot6h

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 ow.ly/bc4050VucbH

AbCellera to Participate at Upcoming Investor Conferences in May and June ow.ly/LQ0q50VwXB5

Visit our poster at #festivalofbiologics in San Diego to learn how we’re leveraging our T-cell engager (TCE) platform to design and optimize TCEs for solid tumor targets. Read more about our TCE platform: tinyurl.com/mrh67e5w

Visit our poster at #AACR25 to see how combining diverse CD3- and tumor-binding antibodies and empirically testing for optimal combinations can generate T-cell engagers (TCEs) with in vivo efficacy. Read more about our TCE platform here: tinyurl.com/37p49n32 #ImmunoOncology

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 ow.ly/uCHl50VFJPs

Visit our poster at #SIDSanDiego25 to learn about a novel, fully human and half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis. Read more about our pipeline here: ow.ly/cTE650VMgbU

Visit our poster at #PEGSSummit to learn how multiple T-cell engager (TCE) building blocks can be leveraged to tailor TCE design for diverse tumor targets. Read more about our TCE platform: ow.ly/CNgJ50VO9uK

AbCellera Reports Q1 2025 Business Results ow.ly/LTfX50VPzAn

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting ow.ly/n20p50VQnQn

AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit ow.ly/TLEF50VRmta

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause ow.ly/wZ1o50VSUVU

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 ow.ly/7GH550W1JLI